GeNeuro SA (GNRRF)
- Business Wire
GeNeuro Will Contribute Its Expertise in Human Endogenous Retroviruses to the €6.8M EU-Funded HERVCOV Precision Medicine Project
GENEVA & LYON, France, June 20, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), announces today that its R&D subsidiary GeNeuro Innovation SAS will be the industrial R&D partner of the HERVCOV project funded with a €6.8 million grant from
- Business Wire
GeNeuro Announces Approval of all Resolutions Proposed at 2022 Annual General Meeting
GENEVA, Switzerland, June 02, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 31, 2022. These included among others:
- Business Wire
GeNeuro Announces Successful €7.7 Million Private Placement
GENEVA, May 12, 2022--Regulatory News: NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO
